I just found an article talking about the FDA’s review of a new drug developed by GlaxoSmithKline and Theravance. It’s called Breo and is targeted towards COPD patients. If you’ve always heard “COPD” but don’t know what it is, the acronym stands for Chronic Obstructive Pulmonary Disease and includes chronic bronchitis, emphysema or both. It’s a scary thing. Now if you don’t have COPD, but do suffer from asthma or related lung condition, this drug could still be for you.
Breo is a combination drug containing both fluticasone furoate (corticosteroid) and vilanterol (long-acting beta-agonist). Other drugs similar to this on the market include:
- Advair (fluticasone propionate and salmeterol)
- Symbicort (budesonide and formoterol fumarate dihydrate)
- Dulera (mometasone furoate and formoterol fumarate dihydrate).
Lots of big words in there, but these are all comprised of a steroid and a long-acting bronchodilator or beta-agonist. I tend to always be prescribed the latest and greatest, so I’m wondering if I’ll be switching to this some time in the future. One change Breo brings to the game is one dose a day. Many patients using combo drug inhalers are needing to take them both morning and night.
Also mentioned in the article is Anoro which could be competing with Spiriva. Anoro contains both vilanterol and umeclidinium. Vilanterol, a LABA, is one-half of Breo and umedlidinium is a long-acting muscarinic receptor antagonist. Supposedly this is the first LABA-LAMA combination drug.